within Pharmacolibrary.Drugs.ATC.A;

model A02AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02AD02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Magaldrate is a complex aluminum and magnesium hydroxide antacid used to neutralize stomach acid and relieve symptoms of indigestion, heartburn, or gastritis. It is approved and widely used as an over-the-counter antacid.</p><h4>Pharmacokinetics</h4><p>No clinical pharmacokinetic models with explicit parameter values (bioavailability, clearance, Vd, etc.) for magaldrate in human populations are available in the published literature. Magaldrate acts locally in the gastrointestinal tract and is minimally absorbed; its pharmacokinetics is therefore largely non-systemic.</p><h4>References</h4><ol><li><p>al-Gohary, OM, &amp; Hosny, EA (1997). Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. <i>Pharmaceutica acta Helvetiae</i> 72(2) 81–86. DOI:<a href=\"https://doi.org/10.1016/s0031-6865(96)00059-3\">10.1016/s0031-6865(96)00059-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9112830/\">https://pubmed.ncbi.nlm.nih.gov/9112830</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02AD02;
